Clark Estates Inc. NY Takes Position in Indivior PLC (NASDAQ:INDV)

Clark Estates Inc. NY purchased a new stake in Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 254,100 shares of the company’s stock, valued at approximately $2,477,000. Clark Estates Inc. NY owned approximately 0.18% of Indivior as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Cubist Systematic Strategies LLC lifted its holdings in shares of Indivior by 32.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after acquiring an additional 6,121 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Indivior in the second quarter worth approximately $188,000. VELA Investment Management LLC bought a new stake in Indivior in the 2nd quarter worth $235,000. XTX Topco Ltd bought a new position in shares of Indivior during the second quarter valued at about $249,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Indivior by 14.2% during the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock worth $9,424,000 after purchasing an additional 54,750 shares during the period. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on INDV. Piper Sandler reissued an “overweight” rating and set a $16.00 target price (up from $15.00) on shares of Indivior in a research note on Friday, October 25th. Craig Hallum decreased their target price on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 11th.

Indivior Price Performance

Shares of NASDAQ INDV opened at $11.18 on Wednesday. The firm has a 50-day moving average of $9.53 and a 200 day moving average of $12.42. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $23.22. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.83 and a quick ratio of 0.65.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The business had revenue of $307.00 million during the quarter, compared to analysts’ expectations of $302.25 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. Research analysts anticipate that Indivior PLC will post 1.66 earnings per share for the current fiscal year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.